Researchers at the Francis Crick Institute and the UCL Cancer Institute have identified how different cancers go through some of the same genetic mutations at the same point in their evolution. Their findings could bring us a step closer to an ‘evolutionary rule book’ which could help predict and block cancer’s next move.
The genetic make-up of a tumor changes over time. This is the result of mistakes made when cancerous cells replicate their DNA to create a copy which is needed for the cell to divide. Researchers have previously shown that patients whose tumors have more diverse genetic mutations are less likely to survive, and now they’re working to understand why these mutations occur and if there’s a pattern or order to them.
In their paper, published in Nature today (Wednesday), the research team found that changes in the chromosomes of cancer cells happen frequently and throughout the development of a tumor, and changes which help it survive and grow are more likely to take hold.
In collaboration with the Max Delbrück Center for Molecular Medicine, the team developed a technique that analyses multiple samples from a single tumor to identify chromosomal changes in 1421 tumor samples taken from 394 patients and across 22 types of tumors.
When looking at the nature and timing of these chromosomal changes, they found that often similar chromosomal changes had taken place in different subclones within a tumor from the same patient. These subclones are different populations or groups of cells within the same tumor. This evidence of subclones evolving in parallel was observed in samples taken from 37% of patients (146 patients).
They also identified chromosomal changes that occur across different tumor types at particular stages of cancer evolution, including changes that might help a tumor to evade the immune system or continue to grow despite a lack of oxygen.
In a tumor there are lots of genetic changes taking place. The fact we saw similar chromosomal changes take hold independently within a tumor in separate subclones suggests these changes are important for the tumor and might lead to subclones with them ‘out-competing’ other subclones without them.”
Thomas Watkins, Lead author and PhD student, Cancer Evolution and Genome Instability Laboratory at Crick
Charles Swanton, senior group leader at the Crick and UCL, Cancer Research UK’s chief clinician and consultant oncologist at UCLH, says: “The presence of common changes supports the theory that there are a number of genetic pathways through which tumors must evolve. Identifying these would move us a step closer to writing cancer’s evolutionary rule book.”
Evolutionary catalysts
The team also saw how some changes were common at the beginning of a cancer’s development, while others were more frequent later on, after it has spread to other parts of the body. And there were certain events that acted as a catalyst for mutations. For example, a common phenomenon in cancer called whole genome doubling, where every chromosome is duplicated, appears to open up new evolutionary solutions for the tumor, leading to a wave of late stage mutations.
There was a sense of order in the mutations we identified, with different mutations likely to appear at different points. So these changes, which may seem like chromosomal chaos, could actually be something we could predict. Of course, if you could predict them, this opens the door to scientists and doctors developing new treatments, or roadblocks, which could block these evolutionary pathways.”
Nicholas McGranahan, Group leader of Cancer Genome Evolution Group, UCL Cancer Institute
The researchers are continuing this work, using their new analysis technique on samples taken from patients with lung cancer, as part of Cancer Research UK’s TRACERx project. They hope this will lead to new insights about the genetic changes that drive the spread of this cancer as well as understanding what changes help these tumors to evade the immune system.
This work is supported by Rosetrees Trust.
New trials show promise for immune checkpoint blockers in early-stage lung cancer